# A Study to Assess the Effect of SB 659032 on Platelet Function

> **NCT01750827** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 14 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** SB659032

## Key facts

- **NCT ID:** NCT01750827
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2012-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01750827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01750827, "A Study to Assess the Effect of SB 659032 on Platelet Function". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01750827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*